0

Vanda Pharmaceuticals Announces Positive Results In Schizophrenia Patients Who Relapse

(BiotechPickList) – Today Vanda Pharmacduticals (NASDAQ:VNDA) announced positive results from a Relapse prevention study in patients with Schizophrenia. The trial is known as the REPRIEVE clinical study which was a randomized placebo control study. One thing to note was that… Continue Reading

0

Biomarin Posts Positive Phase 2 Results for Its Dwarfism Drug

(BiotechPickList) – Shares of Biomarin Pharmaceutical (NASDAQ:BMRN) are up about 6% in after hours trade after the company reported positive phase 2 results in children with Achondroplasia — also known as the most common form of human dwarfism. The company’s… Continue Reading

0

FDA Panel Backs New Class Of Medicine For High Cholesterol Drug

Today both Sanofi (NYSE:SNY) and Regeneron Pharmaceuticals (NASDAQ:REGN) won over an FDA panel who agreed to back a cholesterol lowering drug that could possibly end up reducing the risk of patients getting a heart attack. The panel voted 13-3 ,… Continue Reading

0

Rxi Pharmaceuticals: Multiple News This Week And Beyond

It has been a busy few weeks for Rxi Pharmaceuticals (NASDAQ:RXII) as it has released multiple news sources that has garnered a lot of volume over the many trade sessions. For starters Rxi announced a public offering on May 28,… Continue Reading

0

Inovio Pharmaceuticals Partners With GeneOne Life Science For MERS Virus

On May 27, 2015  Inovio Pharmaceuticals (NASDAQ:INO) announced that it had entered into a partnership with GeneOne Life Science for MERS immunotherapy development. MERS is a lethal virus in the Middle East that kills at least 40% of those who are… Continue Reading

0

Celgene Announces Positive Phase 2 Data In Patients With Crohn’s Disease

Today Celgene (NASDAQ:CELG) announced positive phase 2 results for their Crohn’s Disease study. This data was presented at the Digestive Disease Week — DDW — in Washington D.C. This trial was run as a double-blind placebo controlled trial in which… Continue Reading

0

Shares of Newlink Genetics Tumble 26% After Announcing Trial Continuation Of Pancreatic Cancer Study

Shares of Newlink Genetics (NASDAQ:NLNK) are down 26% after an interim look revealed that the study should continue as planned. At first this may sound really bullish, but on the other hand Wall Street was looking for an early stop… Continue Reading

0

Merrimack Continues To Make Progress With Pancreatic Cancer Drug

(BiotechPickList) – Today Merrimack Pharmaceuticals (NASDAQ:MACK) announced that it has initiated a phase 2 trial in patients with metastatic pancreatic cancer. These patients are being directly targeted as an IGF-1 biomarker population. This means that these patients have high levels of… Continue Reading

0

Can-Fite Biopharma Reports Positive Phase 2/3 Results In Patients with Psoriasis

On April 27,  2015 Can-Fite Biopharma (NASDAQ:CANF) reported positive results in a phase 2/3 trial in patients with moderate-severe psoriasis. As soon as the news was announced shares of Can-Fite surged high ending the day up 51.62%. The new data… Continue Reading

0

Alnylam Reports Positive Phase 2 Results In Patisiran Study

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) are up roughly 2% after the company reported positive results in their phase 2 open label extension study –OLE — of Patisiran. This phase 2 trial is treating patients with a disease known as TTR-Amyloidosis,… Continue Reading